




Contact us by email, phone or leave us your message. To know how, click in the bottom button.
Learn moreActOne® starts its activity as specialist in Market Research directed its services to the Pharma Industry…
Learn moreClick in the bottom button to receive or read the ActOne® newsletters about Market Research, multichannel practices…
Learn more
It is with great satisfaction that ActOne is again awarded the status of SME Leader 2015, distinction receiving since 2012 .
Once again, we fill in the IAPMEI requirements and renewed "our" status. This is a very important distinction for us.
Learn more.
As a results of the a mass communication and promotional campaigns together with the medical community in Portugal, 4You platform already accounts for more than 65% of total active physicians and with more than 2700 pharmacies, in addition to other healthcare professionals (pharmacists, dentists, nurses, healthcare institutions, etc.)
Learn more..
The ActOne on its path of growth and with the relationship already established with the Higher Education and Research Groups, recruited in partnership with the Institute of Economics and Management
Learn more.
ActOne received today the SME Leader 2013 certificate fulfilling all the requests required by IAPMEI regulations.
Learn more.
One of the most admired and recognized top 5 multinational pharmaceutical company present in Portugal has won an internal award "Best European CRM Implementation Award" for the implementation of OnePharma CRM.
Learn more.
ActOne® consultancy services are the natural evolution of the experience years with the direct contact with Parma Industry necessities... Learn more.
ActOne® Customer Relationship Intelligence solutions represent a range of services that add value to the client and access to the knowledge... Learn more.
For the ActOne® Market Research (MR) team delivering studies or information are not enough. It wants to be an active partner of the client in the pursuit of a better knowledge to help supporting the decision process. Learn more.